Tirilazad mesylate ophthalmic - InSite Vision

Drug Profile

Tirilazad mesylate ophthalmic - InSite Vision

Alternative Names: ISV 600; Tirilazad mesylate - InSite Vision

Latest Information Update: 22 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharmacia Corporation
  • Developer InSite Vision; Pharmacia Corporation
  • Class Pregnatrienes
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cataracts; Diabetic retinopathy; Macular degeneration

Most Recent Events

  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
  • 01 Dec 1997 InSite Vision is seeking a corporate partner to enter clinical trials
  • 01 Sep 1997 Preclinical development for Cataracts in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top